Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cerexa Inc.
French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.
Plus deals involving Neumora/Vanderbilt, Active Biotech/Oncode, and Bridge/Scripps.
The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.